Symphogen Acquires a Preclinical Cancer Program from Receptor BioLogix
Deal covers pan-HER ligand traps, which may also be used in other diseases.!--h2>
Symphogen has purchased certain assets from Receptor BioLogix related to its preclinical pan-HER ligand traps to treat cancer and other diseases. Symphogen believes this to be a complementary program to its internally developed recombinant polyclonal antibodies.
The complex HER family of receptors and growth factor ligands is dysregulated in about half of all solid cancers. Receptor BioLogix’ pan-HER ligand traps are engineered proteins combining an antibody-like element along with multiple HER receptors. They are designed to block the diverse ligands that stimulate tumor growth.
“Our team has done an outstanding job of advancing our pan-HER ligand traps in the past months, and we concluded that the advantages of now combining our assets with an organization with an analogous approach and greater resources were compelling—we see strong synergies between the two firms,” remarks Dale R. Pfost, Ph.D., former CEO of Receptor BioLogix.